AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

AB Science announced that a confirmatory Phase III trial of masitinib in metastatic castrate resistant prostate cancer has been authorized by the FDA and EMA, with a biomarker that targets patients with less advanced metastatic disease.